UK's NICE poised to reject Gliadel Implant
The National Institute for Health and Clinical Excellence (NICE), which recommends treatments under the National Health System in England and Wales, is poised to deny potentially life-prolonging new treatments to patients with some of the most aggressive forms of brain cancer, despite acknowledging that the treatments work.
A preliminary announcement that Gliadel (carmustine) Implants and temozolomide, the first proven effective treatments for over 20 years, will not be provided free on the NHS for newly-diagnosed subjects has left medical and patient communities stunned, says Link Pharmaceuticals, which licensed the product for the UK and Ireland from US firm Guilford Pharmaceuticals in 2002.
The NICE appraisal committee is to reconvene on February 28 for their second and final meeting that will determine the NHS availability of these treatments to patients with life-threatening brain tumours.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze